CCL5 and breast carcinoma: In addition, ZA also reduces the number and persistence of disseminated tumor cells in the bone marrow of patients with breast cancer [101, 102], through inhibiting chemokine C-C motif ligand 5 (CCL5)/chemokine receptor (CCR5) and IL-17B/17-BR [103].